Literature DB >> 7570847

Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni.

I R Viana1, A Sher, O S Carvalho, C L Massara, S M Eloi-Santos, E J Pearce, D G Colley, G Gazzinelli, R Correa-Oliveira.   

Abstract

During human schistosomiasis host responses to antigens of various parasite life-cycle stages may contribute to whether the severe, hepatosplenic state develops or the patient remains relatively asymptomatic throughout infection, and may play a role in resistance. This study evaluated production of interferon gamma (IFN-gamma) in vitro by schistosome antigen-stimulated peripheral blood mononuclear cells (PBMCs) from asymptomatic patients, and by PBMCs from apparently uninfected, untreated persons living in areas endemic for Schistosoma mansoni ('endemic normals'). IFN-gamma production parallels PBMC proliferation in that schistosomal egg antigens stimulate patent patients' cells poorly, but strongly stimulate PBMCs from 'endemic normals'. This is proportionally true for antigens from adult worms and cercariae. Although asymptomatic patent patients' cells produced little or no IFN-gamma in response to the 3 schistosomal antigenic extracts, their PBMCs, and PBMCs from 'endemic normals', produced expected amounts of IFN-gamma when exposed to phytohaemagglutinin. This implies that persons with patent infections have schistosome antigen-specific defects in their ability to respond to IFN-gamma production that are not exhibited by putatively resistant 'endemic normals'.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7570847     DOI: 10.1016/0035-9203(94)90436-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  26 in total

1.  Factors associated with resistance to Schistosoma mansoni infection in an endemic area of Bahia, Brazil.

Authors:  Ricardo R Oliveira; Joanemile P Figueiredo; Luciana S Cardoso; Rafael L Jabar; Robson P Souza; Martin T Wells; Edgar M Carvalho; Daniel W Fitzgerald; Kathleen C Barnes; Maria Ilma Araújo; Marshall J Glesby
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 2.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

3.  Cytokine control of the granulomatous response in Schistosoma mansoni-infected baboons: role of exposure and treatment.

Authors:  P W Mola; I O Farah; T M Kariuki; M Nyindo; R E Blanton; C L King
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis.

Authors:  Silvia M L Montenegro; Frederico G C Abath; Ana Lúcia C Domingues; Wlademir G Melo; Clarice N L Morais; Eridan M Coutinho; Siddhartha Mahanty; Thomas A Wynn
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees.

Authors:  M Eberl; J A Langermans; P A Frost; R A Vervenne; G J van Dam; A M Deelder; A W Thomas; P S Coulson; R A Wilson
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children.

Authors:  Kirsten E Lyke; Alassane Dicko; Abdoulaye Dabo; Lansana Sangare; Abdoulaye Kone; Drissa Coulibaly; Ando Guindo; Karim Traore; Modibo Daou; Issa Diarra; Marcelo B Sztein; Christopher V Plowe; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2005-12       Impact factor: 2.345

7.  Cytokine secretion profile associated with periportal fibrosis in S. mansoni-infected Egyptian patients.

Authors:  Roba M Talaat; Azza I El-Bassiouny; Ahmed M Osman; Magdy Yossif; Ragia Charmy; Maged M Al-Sherbiny
Journal:  Parasitol Res       Date:  2007-02-25       Impact factor: 2.289

Review 8.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment.

Authors:  Kanji Watanabe; Pauline N M Mwinzi; Carla L Black; Erick M O Muok; Diana M S Karanja; W Evan Secor; Daniel G Colley
Journal:  Am J Trop Med Hyg       Date:  2007-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.